Altoida to Present Poster Presentations Highlighting Augmented Reality-Based Cognitive Assessment at CTAD 2023

WASHINGTON–(BUSINESS WIRE)–#AR—Altoida, a pioneer in developing digital biomarkers of neurological disease using augmented reality and machine learning, announced today it will be presenting poster presentations at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference, held in Boston and online, October 24-27, 2023.

“We look forward to presenting new data at CTAD 2023, that highlight Altoida’s latest research. Our presented data exemplifies our commitment to advancing the field of Alzheimer’s disease through cutting-edge technology and data-driven insights,” said Marc Jones, CEO of Altoida. “Digital biomarkers have the potential to revolutionize our understanding of Alzheimer’s and transform research, clinical trials, and patient diagnosis and treatment. We eagerly anticipate collaborative efforts with our partners in early disease detection and treatment.”

Details of the poster presentations are below:

Poster Title: Correlation between Altoida’s digital cognitive assessment and standard neuropsychological tests in individuals with mild cognitive impairment and cognitively healthy volunteers

Poster Number: P189

Date/Time: Friday, October 27, 8 am to 5 pm

Presenter: Emmanuel Streel, Ph.D., Sr. Medical Affairs Director, Altoida

Poster Title: Building an Evidence Library of Digital Measurement Technologies to Accelerate Endpoint Development in Alzheimer’s Disease and Related Dementias Clinical Trials

Poster Number: P190

Date/Time: Friday, October 27, 8 am to 5 pm

Presenter: Emmanuel Streel, Ph.D., Sr. Medical Affairs Director, Altoida

About Altoida

Altoida is a pioneer in developing digital biomarkers of neurological conditions using augmented reality and machine learning. Our technology platform is designed to enable an objective evaluation of an individual’s cognitive health, which may potentially allow for faster patient selection for clinical trials, as well as sensitive monitoring of disease progression and treatment response. Altoida’s mission is to enable a new era of precision neurology using digital biomarkers. Our proprietary evidence-based platform is founded on more than 20 years of scientific research and published in multiple peer-reviewed papers including Nature Digital Medicine. For more information, visit www.altoida.com. Follow us on Twitter @altoida.

Contacts

Media

Kimberly Ha

KKH Advisors

917-291-5744

kimberly.ha@kkhadvisors.com